11 Oct 2007
Renovo wins European Biotechnica Award 2007
11 Oct 2007 - Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the prevention and reduction of scarring at multiple body sites, is pleased to announce that it has won first prize in the final round of the European Biotechnica Award 2007. This was the first time that the award has been won by a UK biotech company.
The award, which brings with it benefits worth up to 100,000 Euros, is presented by the Deutsche Messe AG to European biotech and life science companies in related fields. The international jury, which was made up of distinguished biotech experts from six countries, selected the winner from a list of 27 applicants. The major criteria in the selection of the award winners were the marketability, relevance and impact of the products under consideration and the existence of a potentially successful marketing concept and strategy.
Christian Wulff, the Premier of Lower Saxony, Dr. Karl-Ludwig Kley, Chairman of the Board of Merck KGaA, Christian Siebert, departmental head at the European Commission, and Stephan Ph. Kühne, who sits on the Board of Management at Deutsche Messe AG, Hannover, presented the prizes in the presence of more than 500 invited people from the worlds of science, business and politics.
Professor Mark W J Ferguson, Chief Executive Officer of Renovo, said:
“We are delighted to be the first UK biotech company to win the European Biotechnica Award. This highly prestigious award, which was judged by an international jury of biotech experts, is further recognition of the strength of Renovo’s research and development expertise, its product pipeline, and the huge potential market for drugs targeted at the prevention and reduction of scarring.”
Professor Dr. Peter J. W. Stadler in his capacity as jury chairman, said:
“The winner Renovo impressed the jury with its high scientific standards, its pioneering products in a very important area of application that has hitherto suffered from low standards of treatment, its strong financial situation and its genuine entrepreneurial spirit.”
For further information please contact:
Renovo Group plc
Professor Mark Ferguson, Chief Executive Officer
+44 (0) 161 606 7222
Simon Bielecki, Head of Communications
+44 (0) 161 606 7328
Tim Anderson/Lisa Baderoon/Mary-Jane Johnson
+44 (0) 20 7466 5000
About the Award
The European Biotechnica Award is Europe´s most important and valuable prize for small and medium-sized enterprises working in biotechnology and life sciences. The Award was presented for the fifth time in 2007, with prizes to the amount of EUR 100,000. This year’s Award Ceremony took place on the occasion of the opening ceremony of BIOTECHNICA on Monday, 8 October 2007, in Hannover, Germany.
The 2nd price was awarded to Genmab S/A, a biotechnology company located in Denmark, and the 3rd prize was awarded to Bavarian Nordic, also based in Denmark.
For further information on the award and photographs please visit
About Renovo Group plc
Renovo is a biopharmaceutical product company and is the world leader in scar prevention and reduction research and the development of drugs to prevent and reduce scarring. The Company has a highly skilled management team with over 30 years of research experience in the field of scarring and significant pharmaceutical industry expertise.
Renovo has a portfolio of drugs which exploit different novel mechanisms of action to prevent and reduce scarring at multiple body sites and to accelerate healing. Juvista ®, Renovo’s lead drug for the prevention and reduction of scarring in the skin has been safely administered to over 1,500 human subjects and has reported statistical and clinical significance in five Phase 2 efficacy trials.
Renovo announced in June 2007 that it had signed an exclusive licensing agreement with Shire plc to develop and commercialise Juvista. The agreement covers every country in the world except the European Union, the rights to which have been retained by Renovo. Under the terms of the deal Renovo has already received an initial payment of US$125 million. Contingent on the successful development and commercialisation of Juvista Renovo will be eligible for further payments of up to $700 million together with escalating royalties on sales
Zesteem®, Renovo’s lead drug for the acceleration of wound healing in the skin, commenced Phase 3 clinical trials in December 2006. Prevascar™ reported statistically significant Phase 2 efficacy data for the prevention and reduction of scarring in the skin in April 2007 and is additionally being investigated for enhancing regeneration of peripheral nerves following injury or trauma.
According to external research, the potential commercial market for prevention and reduction of scarring in the skin is worth, in the order of, $4 billion per annum in the US alone.
For further information on Renovo please visit: www.renovo.com